AI Article Synopsis
- Hepatectomy is a surgery that can help cure a type of liver cancer called hepatocellular carcinoma (HCC), but there's debate about whether extra treatment (called adjuvant therapy) is helpful afterwards.
- The study looked at two groups of HCC patients: one group got extra treatment (adjuvant transarterial chemotherapy) after surgery, while the other group didn't, to see how it affected their recovery.
- The results showed that patients who got the extra treatment had some issues like more blood loss, but those with positive surgical margins (cancer left behind) lived longer if they had the extra treatment compared to those who didn’t.
Article Abstract
Background And Aims: Hepatectomy is a well-established curative treatment for hepatocellular carcinoma. However, the role of adjuvant therapy is controversial. This study examines the efficacy of adjuvant transarterial chemotherapy for hepatocellular carcinoma.
Methods: The data of hepatocellular carcinoma patients undergoing curative hepatectomy was reviewed. Those with adjuvant transarterial chemotherapy were matched with those without using propensity score analysis, by tumour size and number, indocyanine green retention rate, disease staging and Child-Pugh grading. The groups were compared.
Results: Eighty-seven patients with hepatocellular carcinoma who underwent hepatectomy received adjuvant transarterial chemotherapy (TAC group), and were matched with 870 patients who did not (no-TAC group). The groups were largely comparable in patient and disease characteristics, but the TAC group experienced more blood loss, higher transfusion rates, narrower margins and more positive margins. The two groups were found to be comparable in disease-free and overall survival rates. In margin-positive patients, those given TAC survived longer than those without, and margin-positive patients in the TAC group had overall survival rates similar to margin-negative patients in the no-TAC group.
Conclusions: Margin involvement is an adverse factor for survival in HCC. Adjuvant transarterial chemotherapy may offer survival benefits to hepatocellular carcinoma patients with positive surgical margins.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00423-021-02292-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Iodine-131 radioembolization boosts the immune activation enhanced by icaritin/resiquimod in hepatocellular carcinoma.
J Control Release
December 2024
Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Center for Biomedical Imaging, Fudan University, Shanghai 200032, China; Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai 200032, China; Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai 200433, China. Electronic address:
Transarterial radioembolization (TARE) is a recommended locoregional strategy for intermediate hepatocellular carcinoma (HCC), whereas, the effect is insufficient to reverse the immunosuppression tumor microenvironment, and the overall benefits for patients remain to be improved. In this study, a multifunctional microsphere (MS) I-ICT/R848-MS is developed to propose an approach combined with TARE, icaritin (ICT) and immune modulator resiquimod (R848). ICT and iodine-131 (I) radiation can induce immunogenic cell death, which, in combination with R848, will boost dendritic cell (DC) maturation.
View Article and Find Full Text PDFCase report: Microsatellite instability-high pancreas adenosquamous carcinoma with postoperative liver metastasis recurrence treated with multimodality therapy achieving complete pathological response.
Front Immunol
December 2024
Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, China.
Pancreatic adenosquamous carcinoma (PASC) is a rare subtype of pancreatic cancer (PC), with no established consensus on the optimal treatment for postoperative liver metastasis recurrence. We report a case of a 48-year-old male patient who underwent radical surgery and was pathologically diagnosed with microsatellite instability-high (MSI-H) PASC. The patient experienced liver metastasis recurrence following single-agent gemcitabine adjuvant chemotherapy.
View Article and Find Full Text PDFEmbolic and Ablative Therapy for Hepatocellular Carcinoma.
Clin Liver Dis
February 2025
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA. Electronic address:
Article Synopsis
- Locoregional therapies (LRTs) for hepatocellular carcinoma include ablative methods like microwave and radiofrequency ablation, as well as embolic techniques such as transarterial chemoembolization and radioembolization.
- These therapies aim to either cure, bridge, or downstage patients, but they often face challenges with high post-treatment recurrence rates.
- Current research suggests that combining LRTs with systemic therapy could enhance disease control and improve outcomes for patients with liver cancer.
Systemic Therapy for Hepatocellular Carcinoma.
Clin Liver Dis
February 2025
Department of Medicine, Division of Medical Oncology, Duke University Health System, Durham, NC, USA. Electronic address:
Systemic therapy for hepatocellular carcinoma has evolved from sorafenib to now include immune checkpoint blockade, either atezolizumab/bevacizumab or durvalumab/tremelimumab, and soon to include camrelizumab/rivoceranib and nivolumab/ipilimumab. Second-line therapy remains predominantly either a multikinase inhibitor or ramucirumab. Areas of development include testing immune checkpoint-based regimens in the adjuvant setting after surgery, ablation, or transarterial embolization.
View Article and Find Full Text PDFLocoregional Therapies for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
JAMA Netw Open
November 2024
Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Importance: Several locoregional therapies (LRTs) for nonmetastatic hepatocellular carcinoma (HCC) are available; however, a global comparison of the relative efficacy of each is needed.
Objective: To conduct a systematic review and direct, pairwise meta-analytic comparison of all identified randomized clinical trials evaluating the treatment of nonmetastatic HCC.
Data Sources: A comprehensive search of PubMed and the proceedings of the American Society of Clinical Oncology and American Society for Radiation Oncology annual meetings from January 1, 2010, to November 1, 2023, was performed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!